标题 |
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial
新一代口服SERD卡米司群与氟维司群治疗绝经后雌激素受体阳性、HER2阴性晚期乳腺癌(SERENA-2)妇女的比较:一项多剂量、开放标签、随机、2期试验
|
网址 | |
DOI |
暂未提供,该求助的时间将会延长,查看原因?
|
求助人 | |
下载 |